longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

VRDN

VRDN
21.2404.71%( -1.050 )

LongbridgeAI

Stocks in Play: DRI Healthcare Trust

Baystreet
Jun 29, 2026 at 02:10 PM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

10:07 AM EST - DRI Healthcare Trust : DRI Healthcare Trust (TSX: DHT.UN) today commented on Viridian Therapeutics, Inc.'s recently announced approval by the U.S. Food and Drug Administration of Lumvoa™ (veligrotug-vvze) for the treatment of thyroid eye disease. TED is an autoimmune inflammatory disorder of the orbit (eye socket) that affects numerous patients in the U.S. and can cause debilitating and disfiguring eye symptoms (e.g., inflammation, proptosis, and double-vision) with severe disease leading to vision loss. DRI Healthcare Trust shares T.DHT.UN are trading up $0.66 at $18.11.

10:07 AM EST - DRI Healthcare Trust : DRI Healthcare Trust (TSX: DHT.UN) today commented on Viridian Therapeutics, Inc.'s recently announced approval by the U.S. Food and Drug Administration of Lumvoa™ (veligrotug-vvze) for the treatment of thyroid eye disease. TED is an autoimmune inflammatory disorder of the orbit (eye socket) that affects numerous patients in the U.S. and can cause debilitating and disfiguring eye symptoms (e.g., inflammation, proptosis, and double-vision) with severe disease leading to vision loss. DRI Healthcare Trust shares T.DHT.UN are trading up $0.66 at $18.11.

Login to unlock116characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Viridian Therapeutics

Viridian Therapeutics

VRDN.US

Open

--

High

--

Low

--

Prev Close

--

P/ETTM

--

Market Cap

--